SLC16A2 and early-onset autosomal dominant Alzheimer disease: Medium chain triglycerides are currently prescribed for mild to moderate Alzheimer’s disease (AD) patients, and one clinical study has shown that MCT8 improves memory in APOE4-negative patients [20].